David Kandzari, MD, from the Piedmont Heart Institute, led a group of researchers to assess the cost-effectiveness of renal denervation based on clinical event risk reduction, quality of life measures and projected lifetime costs. Data from the SPYRAL HTN-ON MED study was used for the assessment.
“The cost-effectiveness of [renal denervation] was robust across a broad range of scenarios and sensitivity analyses,” the researchers wrote.
The study found that renal denervation had an incremental cost-effectiveness ratio of $32,732 per quality-adjusted life years. Ratios below $50,000 per quality-adjusted life years are considered to indicate an intervention is cost-effective and has “high value,” according to an Aug. 23 TCTMD report.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
